In September, Rob Coppedge of Echo Ventures made waves with a CNBC-published commentary “Digital Health is Dead.” The content of his piece, however, delivered more nuance than its headline. Rob’s issue was not with the rise of an industry that has brought unprecedented consumer focus and innovation to a stagnated healthcare system; his critique was instead focused on the buzzword-focused ecosystem that has grown up around it. The final section of his piece is titled “Digital Health is Dead - Now the Work Begins.”
A week later, I gave a keynote at the Stanford’s Health Care Innovation Summit 2017, where I argued that an unlikely, and often-overlooked group will have an outsized influence directing that work: HR Benefits Managers at large corporations. (You can get the full event recording here or jump to Sean's talk.)
As much as any other group, these individuals have an ability to demand more of our still-nascent industry — more evidence, more personalization, and more systematic alignment between the interests of vendor, payer, and patient. In the next five years, this group will be the key gatekeepers to determine what is required from digital health companies looking to succeed.
Read More: https://www.omadahealth.com/news/hr-benefits-managers-era-of-digital-health
Via: Omada Health
Via: Endovascular Today
November 29, 2017—Silk Road Medical, Inc. announced data from the ROADSTER 1 and 2 trials demonstrating the safety and efficacy of the company’s Enroute transcarotid neuroprotection and Enroute transcarotid stent system, which are specifically designed and indicated for transcarotid artery revascularization (TCAR). The data were first presented at the 2017 VEITHsymposium, held November 14–18 in New York, New York.
OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman Responsibilities
Office of the President continues to perform the duties of President and CEO
Outset Medical Expands Senior Leadership Team by Adding Chief Operating Officer and Commercial Strategy VP
Via: Yahoo! Finance
Outset Medical, a commercial-stage company delivering new technology into the $13 billion global dialysis market, today announced the appointment of two new executives: Martin Vazquez, who joins the company as Chief Operating Officer, and Chad Hoskins as Vice President, Commercial and Corporate Strategy.
Q3 Cash Balance of $113.6M — Cash through Q3 2019
Diabetes is one of the most pervasive and expensive chronic diseases: It affects an estimated 30.3 million people in the United States and costs a staggering $245 billion per year to treat. In addition there are 84.1 million adults in the United States with high blood sugar levels in danger of developing type 2 diabetes. It is widely acknowledged that the most effective method of treating these prediabetics so they don’t become full-fledged diabetics is diabetes prevention programs (DPPs) that follow a protocol validated by the Centers for Disease Control and Prevention (CDC). But the challenge has been to get people to enroll in them in the first place and stick with them if they do.